Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Vitamin D3 attenuates SARS‐CoV‐2 nucleocapsid protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR‐BRCC3 signaling pathway in vitro and in vivo

Chen et al., MedComm, doi:10.1002/mco2.318
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 109 treatments. c19early.org
In Vitro and mouse study showing that vitamin D3 attenuates SARS-CoV-2 nucleocapsid protein-induced hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway. In human bronchial epithelial cells overexpressing the N protein, vitamin D3 dose-dependently reduced IL-6 and IL-1β expression and secretion. Authors find that vitamin D3 inhibited N protein-triggered NLRP3 inflammasome activation, an effect enhanced by NLRP3 and caspase-1 inhibitors or siRNAs. Vitamin D3 increased NLRP3 ubiquitination and VDR-NLRP3 binding while decreasing BRCC3-NLRP3 association. In N protein-expressing mice, vitamin D3 improved lung injury and decreased NLRP3 inflammasome activation and hyperinflammation in a VDR-dependent manner.
21 preclinical studies support the efficacy of vitamin D for COVID-19:
Vitamin D has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function20-23. Vitamin D inhibits SARS-CoV-2 replication in vitro10,17, mitigates lung inflammation, damage, and lethality in mice with an MHV-3 model for β-CoV respiratory infections10,17, reduces SARS-CoV-2 replication in nasal epithelial cells via increased type I interferon expression13, downregulates proinflammatory cytokines IL-1β and TNF-α in SARS-CoV-2 spike protein-stimulated cells9, attenuates nucleocapsid protein-induced hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway14, may be neuroprotective by protecting the blood-brain barrier, reducing neuroinflammation, and via immunomodulatory effects24, downregulates ACE2 and TMPRSS2 in human trophoblasts and minimizes spike protein-induced inflammation12, minimizes platelet aggregation mediated by SARS-CoV-2 spike protein via inhibiting integrin αIIbβ3 outside-in signaling8, and improves regulatory immune cell levels and control of proinflammatory cytokines in severe COVID-1925. Symptomatic COVID-19 is associated with a lower frequency of natural killer (NK) cells and vitamin D has been shown to improve NK cell activity26,27.
Chen et al., 21 Jun 2023, peer-reviewed, 11 authors. Contact: hongbinsong@263.net, bianxiuwu@263.net.
This PaperVitamin DAll
Vitamin D3 attenuates SARS‐CoV‐2 nucleocapsid protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR‐BRCC3 signaling pathway in vitro and in vivo
Mingliang Chen, Ying He, Xiaofeng Hu, Xunhu Dong, Zexuan Yan, Qingning Zhao, Jingyuan Li, Dongfang Xiang, Yong Lin, Ph.D Hongbin Song, M.D Xiuwu Bian
MedComm, doi:10.1002/mco2.318
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-caused coronavirus disease 2019 (COVID-19) is a global crisis with no satisfactory therapies. Vitamin D3 (VD3) is considered a potential candidate for COVID-19 treatment; however, little information is available regarding the exact effects of VD3 on SARS-CoV-2 infection and the underlying mechanism. Herein, we confirmed that VD3 reduced SARS-CoV-2 nucleocapsid (N) protein-caused hyperinflammation in human bronchial epithelial (HBE) cells. Meanwhile, VD3 inhibited the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation in N protein-overexpressed HBE (HBE-N) cells. Notably, the inhibitors of caspase-1, NLRP3, and NLRP3 or caspase-1 small interference RNA (siRNA) enhanced VD3-induced NLRP3 inflammasome inactivation, with subsequent suppression of interleukin-6 (IL6) and IL1β release in HBE-N cells, which were abolished by the NLRP3 agonist. Moreover, VD3 increased NLRP3 ubiquitination (Ub-NLRP3) expression and the binding of the VDR with NLRP3, with decreased BRCA1/BRCA2-containing complex subunit 3 (BRCC3) expression and NLRP3-BRCC3 association. VD3-induced Ub-NLRP3 expression, NLRP3 inflammasome inactivation, and hyperinflammation inhibition were improved by the BRCC3
AUTHOR CONTRIBUTIONS A C K N O W L E D G M E N T S We are particularly grateful to Figdraw (https://www. figdraw.com/static/index.html) for providing a useful tool to draw the diagram of the mechanism. This work was supported by the National Natural Science Foundation of China (grant numbers: 82073544 and 82202189) and the Beijing Municipal Natural Science Foundation of China (grant number: 7232229). C O N F L I C T O F I N T E R E S T S TAT E M E N T The authors declare no conflict of interest. D ATA AVA I L A B I L I T Y S TAT E M E N T All data and materials are available to the researchers once published. E T H I C S S TAT E M E N T All animal experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health and were approved by the Animal Care and Use Committee of the Army Medical University (AMUWEC20212432, Chongqing, China). O R C I D Xiaofeng Hu https://orcid.org/0000-0003-0569-8535 R E F E R E N C E S S U P P O R T I N G I N F O R M AT I O N Additional supporting information can be found online in the Supporting Information section at the end of this article.
References
Akther, Haque, Park, Kang, Lee, NLRP3 Ubiquitination-A new approach to target NLRP3 inflammasome activation, Int J Mol Sci
Cantorna, Zhu, Froicu, Wittke, Vitamin D status, 1,25dihydroxyvitamin D3, and the immune system, Am J Clin Nutr
Chen, Moriyama, Chang, Ichinohe, Severe acute respiratory syndrome coronavirus Viroporin 3a activates the NLRP3 inflammasome, Front Microbiol
Chen, Zhu, Ran, Lang, Yi et al., Trimethylamine-N-Oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway, J Am Heart Assoc
Dong, He, Ye, Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway, Clin Transl Med
Ebadi, Montano-Loza, Perspective: improving vitamin D status in the management of COVID-19, Eur J Clin Nutr
Freeman, Swartz Targeting the NLRP3 inflammasome in severe COVID-19, Front Immunol
Guo, Cao, Hong, The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status, Mil Med Res
He, Dong, Zhu, Xu, Chen et al., Ultrasoundtriggered microbubble destruction enhances the radiosensitivity of glioblastoma by inhibiting PGRMC1-mediated autophagy in vitro and in vivo, Mil Med Res
Hu, Dong, Wang, Jing, Chen, Vitamin D(3)-vitamin D receptor axis suppresses pulmonary emphysema by maintaining alveolar macrophage homeostasis and function, EBioMedicine
Huang, Ju, Role of vitamin D/VDR nuclear translocation in down-regulation of NF-κB/NLRP3/caspase-1 axis in lupus nephritis, Int Immunopharmacol
Ishizuka, Kurihara, Miura, Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25dihydroxyvitamin D3 from pagetic bone marrow cells, J Steroid Biochem Mol Biol
Jin, Cai, Cheng, A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version), Military Medical Research
Jin, Zhan, Peng, Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version), Mil Med Res
Jolliffe, Camargo, Sluyter, Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials, Lancet Diabetes Endocrinol
Juliana, Fernandes-Alnemri, Kang, Farias, Qin et al., Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation, J Biol Chem
Lara, Macías-Verde, Burgos-Burgos, Age-induced NLRP3 inflammasome over-activation increases lethality of SARS-CoV-2 pneumonia in elderly patients, Aging Dis
Li, Zhong, Li, Wang, Effects of 1,25-dihydroxyvitamin D3 on experimental periodontitis and AhR/NF-κB/NLRP3 inflammasome pathway in a mouse model, J Appl Oral Sci
Liu, Qian, Cao, Post-translational modification control of innate immunity, Immunity
Liu, Shi, Cai, Pathological changes in the lungs and lymphatic organs of 12 COVID-19 autopsy cases, Natl Sci Rev
Lucchesi, Silimbani, Musuraca, Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease, J Med Virol
Ma, Zhu, Zhao, SARS-CoV-2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage, EMBO J
Manchanda, Bid, Vitamin D receptor and type 2 diabetes mellitus: Growing therapeutic opportunities, Indian J Hum Genet
Mangan, Olhava, Roush, Seidel, Glick et al., Targeting the NLRP3 inflammasome in inflammatory diseases, Nat Rev Drug Discov
Martineau, Jolliffe, Hooper, Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data, BMJ
Nieto-Torres, Verdiá-Báguena, Jimenez-Guardeño, Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome, Virology
Pan, Shen, Yu, SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation, Nat Commun
Py, Kim, Vakifahmetoglu-Norberg, Yuan, Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity, Mol Cell
Rao, Chen, Wu, Vitamin D receptor inhibits NLRP3 activation by impeding its BRCC3-mediated deubiquitination, Front Immunol
Ren, Zhang, Xiao, ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination, EMBO J
Rodrigues, De Sá, Ishimoto, Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J Exp Med
Sassi, Tamone, Amelio, Vitamin D: Nutrient, hormone, and immunomodulator, Nutrients
Sowa, Bennett, Gygi, Harper, Defining the human deubiquitinating enzyme interaction landscape, Cell
Tang, Tu, Lin, Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia, J Exp Med
Teshome, Adane, Girma, Mekonnen, The impact of vitamin D level on COVID-19 infection: Systematic review and meta-analysis, Front Public Health
Wei, Christakos, Mechanisms underlying the regulation of innate and adaptive immunity by vitamin D, Nutrients
White, Reeves, Pharmacological properties of foods and nutrients, J Ethn Subst Abuse
Wu, Wang, Cai, Effects of different therapeutic schedules on patients with COVID-19: A prospective casecontrol study in China, Advanced Gut & Microbiome Research
Xin, Zhai, 1,25-Dihydroxy Vitamin D(3) attenuates the oxidative stress-mediated inflammation induced by PM(2.5)via the p38/NF-κB/NLRP3 pathway, Inflammation
Xu, Ong, Wang, Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines, Mil Med Res
Zemb, Bergman, Camargo, Vitamin D deficiency and the COVID-19 pandemic, J Glob Antimicrob Resist
Zeng, Xie, Feng, Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice, EBioMedicine
Zhao, Di, Xu, The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies, Cytokine Growth Factor Rev
{ 'indexed': { 'date-parts': [[2023, 12, 26]], 'date-time': '2023-12-26T08:13:55Z', 'timestamp': 1703578435394}, 'reference-count': 43, 'publisher': 'Wiley', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2023, 6, 21]], 'date-time': '2023-06-21T00:00:00Z', 'timestamp': 1687305600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100001809', 'name': 'National Natural Science Foundation of China', 'doi-asserted-by': 'publisher', 'award': ['82073544', '82202189']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023, 8]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Severe acute respiratory syndrome coronavirus 2 ' '(SARS‐CoV‐2) infection‐caused coronavirus disease 2019 (COVID‐19) is a global crisis with no ' 'satisfactory therapies. Vitamin D3 (VD3) is considered a potential candidate for COVID‐19 ' 'treatment; however, little information is available regarding the exact effects of VD3 on ' 'SARS‐CoV‐2 infection and the underlying mechanism. Herein, we confirmed that VD3 reduced ' 'SARS‐CoV‐2 nucleocapsid (N) protein‐caused hyperinflammation in human bronchial epithelial ' '(HBE) cells. Meanwhile, VD3 inhibited the NOD‐like receptor family pyrin domain containing 3 ' '(NLRP3) inflammasome activation in N protein‐overexpressed HBE (HBE‐N) cells. Notably, the ' 'inhibitors of caspase‐1, NLRP3, and <jats:italic>NLRP3</jats:italic> or ' '<jats:italic>caspase‐1</jats:italic> small interference RNA (siRNA) enhanced VD3‐induced ' 'NLRP3 inflammasome inactivation, with subsequent suppression of interleukin‐6 (IL6) and IL1β ' 'release in HBE‐N cells, which were abolished by the NLRP3 agonist. Moreover, VD3 increased ' 'NLRP3 ubiquitination (Ub‐NLRP3) expression and the binding of the VDR with NLRP3, with ' 'decreased BRCA1/BRCA2‐containing complex subunit 3 (BRCC3) expression and NLRP3‐BRCC3 ' 'association. VD3‐induced Ub‐NLRP3 expression, NLRP3 inflammasome inactivation, and ' 'hyperinflammation inhibition were improved by the BRCC3 inhibitor or ' '<jats:italic>BRCC3</jats:italic> siRNA, which were attenuated by the vitamin D receptor (VDR) ' 'antagonist or <jats:italic>VDR</jats:italic> siRNA in HBE‐N cells. Finally, the results of ' 'the in vivo study in AAV‐Lung‐enhanced\u2002green\u2002fluorescent\u2002protein‐N‐infected ' 'lungs were consistent with the findings of the in vitro experiment. In conclusion, VD3 ' 'attenuated N protein‐caused hyperinflammation by inactivating the NLRP3 inflammasome ' 'partially through the VDR‐BRCC3 signaling pathway.</jats:p>', 'DOI': '10.1002/mco2.318', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 24]], 'date-time': '2023-06-24T07:17:35Z', 'timestamp': 1687591055000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Vitamin D3 attenuates SARS‐CoV‐2 nucleocapsid protein‐caused hyperinflammation by inactivating ' 'the NLRP3 inflammasome through the VDR‐BRCC3 signaling pathway in vitro and in vivo', 'prefix': '10.1002', 'volume': '4', 'author': [ { 'given': 'Mingliang', 'family': 'Chen', 'sequence': 'first', 'affiliation': [ { 'name': 'Institute of Pathology and Southwest Cancer Centre Southwest ' 'Hospital Army Medical University Chongqing China'}, { 'name': 'Institute of Toxicology School of Military Preventive Medicine ' 'Army Medical University Chongqing China'}]}, { 'given': 'Ying', 'family': 'He', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Ultrasound Xinqiao Hospital Army Medical ' 'University Chongqing China'}]}, { 'ORCID': 'http://orcid.org/0000-0003-0569-8535', 'authenticated-orcid': False, 'given': 'Xiaofeng', 'family': 'Hu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Health Supervision and Surveillance Chinese PLA ' 'Center for Disease Control and Prevention Beijing China'}]}, { 'given': 'Xunhu', 'family': 'Dong', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Toxicology School of Military Preventive Medicine ' 'Army Medical University Chongqing China'}]}, { 'given': 'Zexuan', 'family': 'Yan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Pathology and Southwest Cancer Centre Southwest ' 'Hospital Army Medical University Chongqing China'}]}, { 'given': 'Qingning', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Pathology and Southwest Cancer Centre Southwest ' 'Hospital Army Medical University Chongqing China'}]}, { 'given': 'Jingyuan', 'family': 'Li', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Pathology and Southwest Cancer Centre Southwest ' 'Hospital Army Medical University Chongqing China'}]}, { 'given': 'Dongfang', 'family': 'Xiang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Pathology and Southwest Cancer Centre Southwest ' 'Hospital Army Medical University Chongqing China'}]}, { 'given': 'Yong', 'family': 'Lin', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Pathology and Southwest Cancer Centre Southwest ' 'Hospital Army Medical University Chongqing China'}]}, { 'given': 'Hongbin', 'family': 'Song', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Health Supervision and Surveillance Chinese PLA ' 'Center for Disease Control and Prevention Beijing China'}]}, { 'given': 'Xiuwu', 'family': 'Bian', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Pathology and Southwest Cancer Centre Southwest ' 'Hospital Army Medical University Chongqing China'}]}], 'member': '311', 'published-online': {'date-parts': [[2023, 6, 21]]}, 'reference': [ {'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s40779-020-00240-0'}, {'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/nsr/nwaa247'}, { 'issue': '1', 'key': 'e_1_2_10_4_1', 'first-page': '1', 'article-title': 'Pharmacological properties of foods and nutrients', 'volume': '15', 'author': 'White JV', 'year': '2008', 'journal-title': 'J Ethn Subst Abuse'}, { 'issue': '1', 'key': 'e_1_2_10_5_1', 'first-page': '22', 'article-title': 'Role of adjunctive treatment strategies in COVID‐19 and a review of ' 'international and national clinical guidelines', 'volume': '7', 'author': 'Xu X', 'year': '2020', 'journal-title': 'Mil Med Res'}, {'key': 'e_1_2_10_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ajcn/80.6.1717S'}, {'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.i6583'}, {'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jgar.2020.05.006'}, {'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fpubh.2021.624559'}, {'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nrd.2018.97'}, { 'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cytogfr.2021.06.002'}, {'key': 'e_1_2_10_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.26217'}, {'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1084/jem.20201707'}, {'key': 'e_1_2_10_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.14336/AD.2020.0601'}, { 'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-021-25015-6'}, { 'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ebiom.2021.103803'}, { 'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'crossref', 'unstructured': 'XinL CheB ZhaiB et\xa0al.1 25‐Dihydroxy Vitamin D(3) attenuates the ' 'oxidative stress‐mediated inflammation induced by PM(2.5)via the ' 'p38/NF‐κB/NLRP3 pathway.Inflammation.2019;42(2):702‐713.', 'DOI': '10.1007/s10753-018-0928-y'}, { 'key': 'e_1_2_10_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1590/1678-7757-2018-0713'}, {'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/ctm2.312'}, {'key': 'e_1_2_10_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms22168780'}, { 'key': 'e_1_2_10_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.molcel.2012.11.009'}, {'key': 'e_1_2_10_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2019.02783'}, {'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4103/0971-6866.107975'}, {'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/nu10111656'}, { 'key': 'e_1_2_10_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.intimp.2021.108131'}, { 'key': 'e_1_2_10_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ebiom.2019.06.039'}, { 'key': 'e_1_2_10_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.immuni.2016.06.020'}, {'key': 'e_1_2_10_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1084/jem.20182091'}, {'key': 'e_1_2_10_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s40779-020-0233-6'}, { 'issue': '1', 'key': 'e_1_2_10_30_1', 'first-page': '41', 'article-title': 'Chemoprophylaxis, diagnosis, treatments, and discharge management of ' 'COVID‐19: An evidence‐based clinical practice guideline (updated ' 'version)', 'volume': '7', 'author': 'Jin YH', 'year': '2020', 'journal-title': 'Mil Med Res'}, {'key': 'e_1_2_10_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41430-020-0661-0'}, {'key': 'e_1_2_10_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/nu7105392'}, { 'key': 'e_1_2_10_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-8587(21)00051-6'}, {'key': 'e_1_2_10_34_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1155/2022/7009876'}, {'key': 'e_1_2_10_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fimmu.2020.01518'}, { 'key': 'e_1_2_10_36_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.virol.2015.08.010'}, {'key': 'e_1_2_10_37_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fmicb.2019.00050'}, {'key': 'e_1_2_10_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.15252/embj.2021108249'}, { 'key': 'e_1_2_10_39_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2009.04.042'}, {'key': 'e_1_2_10_40_1', 'doi-asserted-by': 'publisher', 'DOI': '10.15252/embj.2018100376'}, {'key': 'e_1_2_10_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/JAHA.117.006347'}, { 'key': 'e_1_2_10_42_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jsbmb.2004.03.025'}, { 'issue': '1', 'key': 'e_1_2_10_43_1', 'first-page': '9', 'article-title': 'Ultrasound‐triggered microbubble destruction enhances the ' 'radiosensitivity of glioblastoma by inhibiting PGRMC1‐mediated ' 'autophagy in vitro and in vivo', 'volume': '9', 'author': 'He Y', 'year': '2022', 'journal-title': 'Mil Med Res'}, {'key': 'e_1_2_10_44_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1074/jbc.M112.407130'}], 'container-title': 'MedComm', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/mco2.318', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 6]], 'date-time': '2023-09-06T16:28:59Z', 'timestamp': 1694017739000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/mco2.318'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 6, 21]]}, 'references-count': 43, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2023, 8]]}}, 'alternative-id': ['10.1002/mco2.318'], 'URL': 'http://dx.doi.org/10.1002/mco2.318', 'relation': {}, 'ISSN': ['2688-2663', '2688-2663'], 'subject': [], 'container-title-short': 'MedComm', 'published': {'date-parts': [[2023, 6, 21]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit